BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
Business Wire•23/10/2026•10:15 ET
0
Key Highlights
- ➤TEVIMBRA combination median OS reached 27.0 months, with hazard ratio 0.65 versus trastuzumab.
- ➤ZIIHERA plus chemotherapy median OS reached 22.9 months versus 19.6 months for trastuzumab.
- ➤TEVIMBRA addition extended median OS four months versus ZIIHERA plus chemotherapy.
- ➤TEVIMBRA-containing regimen delivered 39.8% estimated 36-month overall survival.
- ➤TEVIMBRA combination median PFS reached 12.7 months versus 8.3 months for trastuzumab.
Expert Statements
Mark Lanasa, Chief Medical Officer, Solid Tumors at BeOne
“Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 status. The magnitude of the survival benefit previously demonstrated with TEVIMBRA plus ZIIHERA and chemotherapy versus trastuzumab plus chemotherapy increased after longer follow-up, with nearly 40% of patients receiving the TEVIMBRA-containing regimen alive at three years, representing a compelling result in this challenging disease area.”
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months
Get started
Create a free account to read the full story.